Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion 1 – Immunotherapy of cancer

3770 - Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma


28 Sep 2019


Poster Discussion 1 – Immunotherapy of cancer


Zhitao Ying


Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253


Z. Ying1, T. He2, X. Wang1, W. Zheng1, N. Lin1, M. Tu1, Y. Xie1, L. Ping1, C. Zhang1, W. Liu1, L. Deng1, F. Qi2, X. Lu2, Y. Ding2, Y. Song1, J. Zhu1

Author affiliations

  • 1 Peking University Cancer Hospital & Institute, Peking University Cancer Hospital & Institute, 100142 - beijing/CN
  • 2 Beijing Immunochina Pharmaceuticals, Beijing Immunochina Pharmaceuticals Co., Ltd., 100089 - Beijing/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3770


CD19-targeted chimeric antigen receptor-T (CAR-T) cells with CD28 or 4-1BB (28z CAR-T and BBz CAR-T) have shown great promise to treat relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) and B cell non-Hodgkin lymphoma (B-NHL). However, studies comparing the clinical outcomes of 28z CAR-T versus BBz CAR-T are lacking. Analysis of our previous double-arm clinical study of 28z CAR-T and BBz CAR-T in treatment of r/r B-ALL (18 cases for each arm) revealed that BBz CAR-T showed shorter initial response time, higher tumor-killing capacity, higher overall survival rate, longer persistence, and less severe cytokine release syndrome and neurotoxicity than 28z CAR-T. This study investigated the efficacy and toxicity of both CAR-T types in B-NHL patients.


BBz CAR-T and 28z CAR-T were prepared under identical manufacturing processes. Patients with r/r B-NHL were pre-treated with fludarabine and cyclophosphamide, and infused with 28z or BBz CAR-T. Tumor burden, CAR-T persistence and adverse events were monitored. The CAR-T that induced dose-limiting toxicity in less than one patient was further evaluated based on dose escalation.


Six patients were treated at the dose of 0.75-5 × 105/kg. Both types of CAR-T cells showed similar antitumor efficacies, with a complete response (CR) rate of 67% within three months. Cytokines including interleukin (IL)-6 and IL-10 were increased after CAR-T infusion. The peak levels of IL-6 and IL-10 were much higher in the 28z CAR-T cohort. Severe cytokine release syndrome (CRS), CAR-T cell related encephalopathy syndrome (CRES) (≥ grade 3), and one death occurred in the 28z CAR-T cohort, resulting in the termination of recruitment of this cohort. Six more patients received BBz CAR-T cells at a dose of 1 × 106/kg with one-month CR rate of 83% and only grade 1/2 adverse events.


BBz CAR-T showed similar antitumor activity, but a more favorable safety profile, compared with 28z CAR-T. This study proved the competence of BBz CAR-T in B-NHL therapy, at least under our manufacturing process.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Peking University Cancer Hospital & Institute.


Immunochina Pharmaceuticals Co., Ltd.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.